Pulmonary Arterial Hypertension Market Size and Share by 2028
The pulmonary arterial hypertension market is expected to grow from US$ 7,369.89 million in 2021 to US$ 10,889.08 million by 2028; it is estimated to grow at a CAGR of 5.8% from 2022 to 2028.
The pulmonary arterial hypertension market is segmented on the basis of drug, type, route of administration, distribution channel, and geography. The report offers insights and in-depth analysis of the pulmonary arterial hypertension market, emphasizing various parameters such as dynamics, trends, and opportunities of the market and competitive landscape analysis of leading market players across various regions. It also includes the impact analysis of COVID–19 pandemic on pulmonary arterial hypertension market across the regions.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Pulmonary Arterial Hypertension Market: Strategic Insights
Market Size Value in US$ 7,369.89 Million in 2021 Market Size Value by US$ 10,889.08 Million by 2028 Growth rate CAGR of 5.8% from 2022 to 2028 Forecast Period 2022-2028 Base Year 2021
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Pulmonary Arterial Hypertension Market: Strategic Insights
| Market Size Value in | US$ 7,369.89 Million in 2021 |
| Market Size Value by | US$ 10,889.08 Million by 2028 |
| Growth rate | CAGR of 5.8% from 2022 to 2028 |
| Forecast Period | 2022-2028 |
| Base Year | 2021 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Market Insights
Rising Approvals of Pulmonary Arterial Hypertension Drugs Drives Market Growth
- In September 2022, Toray Industries, Inc. received approval from China’s National Medical Products Administration (NMPA) for Careload tablets to treat pulmonary arterial hypertension (PAH). Careload is an orally administered sustained-release formulation of beraprost sodium, a prostacyclin derivative (PGI2).
- In May 2022, United Therapeutic Corporation received US Food and Drug Administration (FDA) approval for Tyvaso DPI (treprostinil) inhalation powder to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) and pulmonary arterial hypertension (PAH; WHO Group 1) to enhance exercise ability.
- In November 2021, the US FDA granted tentative approval for Yutrepia (treprostinil) inhalation powder. Yutrepia is indicated to treat PAH to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms.
- In July 2021, The Janssen Pharmaceutical Companies of Johnson & Johnson received FDA approval for UPTRAVI (selexipag) injection for intravenous (IV) to treat PAH; WHO Group I in adult patients with WHO functional class (FC) II–III, who are temporarily unable to take oral therapy.
- In August 2021, Aerami Therapeutics, Inc. announced that the FDA granted the company orphan drug designation for imatinib to treat PAH patients. AER– 901, a drug-device combination product candidate for inhaled imatinib for the treatment of PAH, is in a Phase 1 trial with completion targeted for the end of 2021.
The rising approvals of pulmonary arterial hypertension drugs across the world boost the growth of the pulmonary arterial hypertension market.
Drug-Based Insights
Based on drug, the pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. The prostacyclin and prostacyclin analogs segment held the largest market share in 2021 and is anticipated to register the highest CAGR during 2022–2028. Prostacyclin is a small lipid eicosanoid molecule, also known as prostaglandin, I-2 (PGI-2), produced by endothelial cells and acts locally, inhibiting platelet activation and causing vasodilation. Prostacyclin dilates blood vessels, improves blood flow by preventing the proliferation of vascular smooth muscle cells, and prevents blood clotting by inhibiting platelet aggregation. Prostacyclin analogs have been developed as therapies for PAH. PAH prostacyclin analogs are synthetic forms of prostacyclin, a natural substance produced in the body. Patients affected by PAH tend to have reduced prostacyclin levels, leading to blood vessel constriction and hypertension. PAH prostacyclin analogs supplement the requirement and mimic the action of natural prostacyclin to reduce pulmonary hypertension and reduce associated symptoms.
Type-Based Insights
Based on type, the pulmonary arterial hypertension market is bifurcated into branded and generics. The branded segment held a larger market share in 2021 and is expected to register a higher CAGR during the forecast period. A drug company sells a branded drug under a specific name or trademark and that is protected by a patent. Brand-name drugs may be available by prescription or over the counter. Riociguat, sold under the brand name Adempas, is Bayer's medication stimulator of soluble guanylate cyclase. It is used to treat two forms of pulmonary hypertension—chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.
Route of Administration-Based Insights
Based on route of administration, the pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. The oral segment held the largest market share in 2021 and is anticipated to register the highest CAGR during the forecast period. Orally administered agents used for the treatment of symptomatic, moderate-to-severe PAH include sildenafil and the endothelin (ET) receptor antagonists (ERAs), bosentan and sitaxentan (sitaxsentan), and abrisentan oral ET(A) receptor-selective ERA, with higher ET receptor affinity than bosentan. Moreover, new oral drugs for treating PAH include macitentan, riociguat, and treprostinil. Ambrisentan is an endothelin receptor antagonist indicated for treating PAH; WHO Group 1 and delay clinical worsening. In combination with tadalafil, ambrisentan is indicated to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.
Distribution Channel-Based Insights
Based on distribution channel, the pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. The hospital pharmacies and clinics segment held the largest market share in 2021 and is anticipated to register the highest CAGR during the forecast period. Hospital pharmacy strives to continuously maintain and improve patients' medication management and pharmaceutical care to the highest standards in a hospital setting. Pharmacists in this field are responsible for dispensing medications, quality testing, formulating and re-formulating dosage forms, monitoring, reporting drug safety, and preparing budgets for medications.
The pulmonary arterial hypertension market players adopt organic strategies, such as product launch and expansion, to expand their footprint and product portfolio across the world and meet the growing demand. Inorganic growth strategies witnessed in the market are partnerships and collaborations. These growth strategies have allowed the market players to expand their businesses and enhance their geographic presence. Additionally, acquisitions, partnerships, and other growth strategies help strengthen the company’s customer base and increase its product portfolio.
- In September 2022, Lupin launched Sildenafil for oral suspension in the US market with the US FDA approval. The drug is a generic version of Revatio for oral suspension of Viatris Specialty LLC. Sildenafil for oral suspension treats PAH.
- In February 2021, Aerami Therapeutics, Inc. signed an exclusive license and development agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. (Chance) to develop and commercialize Aerami’s drug-device combination product candidate (“AER-901”) for the treatment of PAH in mainland China, Hong Kong, Macau, and Taiwan. Under the agreement, Chance is responsible for the overall development and commercialization of AER-901 for PAH in the territory.
Pulmonary Arterial Hypertension Market Report Scope
Company Profiles
- Johnson & Johnson
- Gilead Sciences Inc
- United Therapeutics Corp
- Bayer AG
- Aerami Therapeutics Holdings Inc
- Novartis AG
- GSK Plc
- Lupin Ltd
- Pfizer Inc
- Teva Pharmaceutical Industries Ltd.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Drugs, Type, Route of Administration, and Distribution Channel
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
The global pulmonary arterial hypertension based on regions is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In 2021, North America held the largest market share. However, the Asia Pacific region is estimated to grow at the fastest CAGR of 6.5% during the forecast period.
Based on drugs, the pulmonary arterial hypertension market is segmented into prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), sGC stimulators, and pde-5 dipsticks. In 2021, the prostacyclin and prostacyclin analogs segment accounted for a larger market share. Also, the same segment is anticipated to register a higher CAGR during the forecast period as the PAH prostacyclin analogs are used as medications to treat pulmonary arterial hypertension (PAH), a condition of high blood pressure in the arteries that carry deoxygenated blood from the heart to the lungs.
Pulmonary arterial hypertension majorly consists of the players, such as Johnson & Johnson, Gilead Sciences Inc, United Therapeutics Corp, Bayer AG, Aerami Therapeutics Holdings Inc, Novartis AG, GSK Plc, Teva Pharmaceutical Industries Ltd, Lupin Ltd, and Pfizer Inc.
The factors driving the growth of pulmonary arterial hypertension are the growing incidence of pulmonary arterial hypertension and the rising approvals of pulmonary arterial hypertension drugs.
The side effects of drugs used for treating pulmonary arterial hypertension are expected to restrict the pulmonary arterial hypertension market growth during the forecast period.
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the lungs' arteries. The increased pressure in the vessels may be caused by an obstruction in the lung's small arteries for various reasons. The exact cause of PAH is unknown, and although treatable, there is no permanent cure for the disease. PAH usually affects women between the ages of 30-60. However, individuals with PAH may go years without a diagnosis, either because the symptoms may be mild, nonspecific, or only present during demanding exercise.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Pulmonary Arterial Hypertension Market – By Drugs
1.3.2 Global Pulmonary Arterial Hypertension Market – By Type
1.3.3 Global Pulmonary Arterial Hypertension Market – By Route of Administration
1.3.4 Global Pulmonary Arterial Hypertension Market – By Distribution Channel
1.3.5 Global Pulmonary Arterial Hypertension Market – By Geography
2. Pulmonary Arterial Hypertension Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Pulmonary Arterial Hypertension Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East and Africa PEST Analysis
4.2.5 South and Central America PEST Analysis
4.3 Experts Opinion
5. Pulmonary Arterial Hypertension Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Incidence of Pulmonary Arterial Hypertension
5.1.2 Rising Approvals of Pulmonary Arterial Hypertension Drugs
5.2 Market Restraints
5.2.1 Side Effects of Drugs Used for Treatment of Pulmonary Arterial Hypertension
5.3 Market Opportunities
5.3.1 Availability of Generics at Affordable Costs Due to Growing Patent Expiration
5.3.2 Drugs Patents Expiration Data
5.4 Future Trend
5.4.1 Rising Clinical Trials for Drugs Development to Treat Pulmonary Arterial Hypertension
5.5 Impact analysis
6. Pulmonary Arterial Hypertension Market – Global Analysis
6.1 Global Pulmonary Arterial Hypertension Market Revenue Forecast and Analysis
6.2 Global Pulmonary Arterial Hypertension Market, By Geography - Forecast and Analysis
6.3 Market Positioning of Key Players
7. Global Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 – by Drugs
7.1 Overview
7.2 Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
7.3 Endothelin Receptor Antagonists (ERAs)
7.3.1 Overview
7.3.2 Endothelin Receptor Antagonists (ERAs): Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Prostacyclin and Prostacyclin Analogs
7.4.1 Overview
7.4.2 Prostacyclin and Prostacyclin Analogs: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
7.5 SGC Stimulators
7.5.1 Overview
7.5.2 SGC Stimulators: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Pde-5 Dipsticks
7.6.1 Overview
7.6.2 Pde-5 Dipsticks: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
8. Global Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 – by Type
8.1 Overview
8.2 Global Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
8.3 Branded
8.3.1 Overview
8.3.2 Branded: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Generics
8.4.1 Overview
8.4.2 Generics: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
9. Global Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 – by Route of Administration
9.1 Overview
9.2 Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
9.3 Oral
9.3.1 Overview
9.3.2 Oral: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Intravenous/ Subcutaneous
9.4.1 Overview
9.4.2 Intravenous/ Subcutaneous: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Inhalational
9.5.1 Overview
9.5.2 Inhalational: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
10. Global Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 – by Distribution Channel
10.1 Overview
10.2 Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
10.3 Hospital Pharmacies and Clinics
10.3.1 Overview
10.3.2 Hospital Pharmacies and Clinics: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Online Pharmacies
10.4.1 Overview
10.4.2 Online Pharmacies: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
10.5 Retail Pharmacies
10.5.1 Overview
10.5.2 Retail Pharmacies: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11. Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 – Geographic Analysis
11.1 North America: Pulmonary Arterial Hypertension Market
11.1.1 Overview
11.1.2 North America: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.3 North America: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.1.4 North America: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.1.5 North America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.6 North America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.1.6.1 US: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.1.1 Overview
11.1.6.1.2 US: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.1.3 US: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.1.6.1.4 US: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.1.6.1.5 US: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.6.1.6 US: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.1.6.2 Canada: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.2.1 Overview
11.1.6.2.2 Canada: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.2.3 Canada: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.1.6.2.4 Canada: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.1.6.2.5 Canada: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.6.2.6 Canada: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.1.6.3 Mexico: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.3.1 Overview
11.1.6.3.2 Mexico: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.1.6.3.3 Mexico: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.1.6.3.4 Mexico: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.1.6.3.5 Mexico: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.6.3.6 Mexico: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.2 Europe: Pulmonary Arterial Hypertension Market
11.2.1 Overview
11.2.2 Europe: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.2.3 Europe: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.2.4 Europe: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.2.5 Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.2.6 Europe: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.2.7 Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
11.2.7.1 UK: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.2.7.1.1 Overview
11.2.7.1.2 UK: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.2.7.1.3 UK: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.2.7.1.4 UK: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.2.7.1.5 UK: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.2.7.1.6 UK: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.2.7.2 Germany: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.2.7.2.1 Overview
11.2.7.2.2 Germany: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.2.7.2.3 Germany: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.2.7.2.4 Germany: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.2.7.2.5 Germany: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.2.7.2.6 Germany: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.2.7.3 France: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.2.7.3.1 Overview
11.2.7.3.2 France: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.2.7.3.3 France: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.2.7.3.4 France: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.2.7.3.5 France: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.2.7.3.6 France: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.2.7.4 Italy: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.2.7.4.1 Overview
11.2.7.4.2 Italy: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.2.7.4.3 Italy: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.2.7.4.4 Italy: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.2.7.4.5 Italy: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.2.7.4.6 Italy: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.2.7.5 Spain: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.2.7.5.1 Overview
11.2.7.5.2 Spain: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.2.7.5.3 Spain: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.2.7.5.4 Spain: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.2.7.5.5 Spain: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.2.7.5.6 Spain: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.2.7.6 Rest of Europe: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.2.7.6.1 Overview
11.2.7.6.2 Rest of Europe: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.2.7.6.3 Rest of Europe: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.2.7.6.4 Rest of Europe: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.2.7.6.5 Rest of Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.2.7.6.6 Rest of Europe: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.3 Asia Pacific: Pulmonary Arterial Hypertension Market
11.3.1 Overview
11.3.2 Asia Pacific: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.3.3 Asia Pacific: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.3.4 Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.3.5 Asia Pacific: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.3.6 Asia Pacific: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.3.7 Asia Pacific: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
11.3.7.1 China: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.3.7.1.1 Overview
11.3.7.1.2 China: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.3.7.1.3 China: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.3.7.1.4 China: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.3.7.1.5 China Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.3.7.1.6 China Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.3.7.2 Japan: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.3.7.2.1 Overview
11.3.7.2.2 Japan: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.3.7.2.3 Japan: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.3.7.2.4 Japan: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.3.7.2.5 Japan: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.3.7.2.6 Japan: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.3.7.3 India: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.3.7.3.1 Overview
11.3.7.3.2 India: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.3.7.3.3 India: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.3.7.3.4 India: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.3.7.3.5 India: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.3.7.3.6 India: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.3.7.4 South Korea: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.3.7.4.1 Overview
11.3.7.4.2 South Korea: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.3.7.4.3 South Korea: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.3.7.4.4 South Korea: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.3.7.4.5 South Korea: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.3.7.4.6 South Korea: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.3.7.5 Australia: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.3.7.5.1 Overview
11.3.7.5.2 Australia: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.3.7.5.3 Australia: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.3.7.5.4 Australia: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.3.7.5.5 Australia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.3.7.5.6 Australia: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.3.7.6 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.3.7.6.1 Overview
11.3.7.6.2 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.3.7.6.3 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.3.7.6.4 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.3.7.6.5 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.3.7.6.6 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.4 South and Central America Pulmonary Arterial Hypertension Market
11.4.1 Overview
11.4.2 South and Central America: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.4.3 South and Central America: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.4.4 South and Central America: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.4.5 South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.4.6 South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.4.7 South and Central America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
11.4.7.1 Brazil: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.4.7.1.1 Overview
11.4.7.1.2 Brazil: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.4.7.1.3 Brazil: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.4.7.1.4 Brazil: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.4.7.1.5 Brazil: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.4.7.1.6 Brazil: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.4.7.2 Argentina: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.4.7.2.1 Overview
11.4.7.2.2 Argentina: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.4.7.2.3 Argentina: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.4.7.2.4 Argentina: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.4.7.2.5 Argentina: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.4.7.2.6 Argentina: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.4.7.3 Rest of South and Central America: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.4.7.3.1 Overview
11.4.7.3.2 Rest of South and Central America: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.4.7.3.3 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.4.7.3.4 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.4.7.3.5 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.4.7.3.6 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.5 Middle East & Africa Pulmonary Arterial Hypertension Market
11.5.1 Overview
11.5.2 Middle East & Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.5.3 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.5.4 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.5.5 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.5.6 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.5.7 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
11.5.7.1 UAE: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
11.5.7.1.1 Overview
11.5.7.1.2 UAE: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.5.7.1.3 UAE: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.5.7.1.4 UAE: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.5.7.1.5 UAE: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.5.7.1.6 UAE: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.5.7.2 Saudi Arabia: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
11.5.7.2.1 Overview
11.5.7.2.2 Saudi Arabia: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.5.7.2.3 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.5.7.2.4 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.5.7.2.5 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.5.7.2.6 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.5.7.3 South Africa: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
11.5.7.3.1 Overview
11.5.7.3.2 South Africa: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.5.7.3.3 South Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.5.7.3.4 South Africa: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.5.7.3.5 South Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.5.7.3.6 South Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
11.5.7.4 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
11.5.7.4.1 Overview
11.5.7.4.2 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
11.5.7.4.3 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)
11.5.7.4.4 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)
11.5.7.4.5 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)
11.5.7.4.6 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)
12. Impact Of COVID-19 Pandemic on Pulmonary Arterial Hypertension Market
12.1 North America: Impact Assessment of COVID-19 Pandemic
12.2 Europe: Impact Assessment of COVID-19 Pandemic
12.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
12.4 South & Central America: Impact Assessment of COVID-19 Pandemic
12.5 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
13. Pulmonary Arterial Hypertension Market – Industry Landscape
13.1 Overview
13.2 Growth Strategies in the Pulmonary Arterial Hypertension Market (%)
13.3 Organic Developments
13.3.1 Overview
13.4 Inorganic Developments
13.4.1 Overview
14. Company Profiles
14.1 Johnson & Johnson
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Gilead Sciences Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 United Therapeutics Corp
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Bayer AG
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Aerami Therapeutics Holdings Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Novartis AG
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 GSK Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Teva Pharmaceutical Industries Ltd
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Lupin Ltd
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Pfizer Inc
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
LIST OF TABLES
Table 1. Drugs Patents Expiration Data
Table 2. North America Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 3. North America Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 4. North America Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 5. North America Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 6. US Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 7. US Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 8. US Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 9. US Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 10. Canada Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 11. Canada Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 12. Canada Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 13. Canada Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 14. Mexico Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 15. Mexico Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 16. Mexico Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 17. Mexico Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 18. Europe Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 19. Europe Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 20. Europe Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 21. Europe Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 22. UK Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 23. UK Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 24. UK Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 25. UK Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 26. Germany Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 27. Germany Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 28. Germany Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 29. Germany Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 30. France Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 31. France Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 32. France Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 33. France Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 34. Italy Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 35. Italy Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 36. Italy Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 37. Italy Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 38. Spain Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 39. Spain Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 40. Spain Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 41. Spain Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 42. Rest of Europe Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 43. Rest of Europe Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 44. Rest of Europe Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 45. Rest of Europe Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 46. Asia Pacific Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 47. Asia Pacific Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 48. Asia Pacific Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 49. Asia Pacific Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 50. China Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 51. China Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 52. China Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 53. China Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 54. Japan Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 55. Japan Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 56. Japan Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 57. Japan Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 58. India Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 59. India Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 60. India Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 61. India Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 62. South Korea Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 63. South Korea Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 64. South Korea Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 65. South Korea Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 66. Australia Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 67. Australia Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 68. Australia Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 69. Australia Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 70. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 71. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 72. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 73. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 74. South and Central America: Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 75. South and Central America: Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 76. South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)
Table 77. South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Million)
Table 78. Brazil: Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 79. Brazil: Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 80. Brazil: Pulmonary Arterial Hypertension Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)
Table 81. Brazil: Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 82. Argentina: Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 83. Argentina: Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 84. Argentina: Pulmonary Arterial Hypertension Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)
Table 85. Argentina: Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 86. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 87. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 88. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration– Revenue and Forecast to 2028 (US$ Million)
Table 89. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 90. Middle East & Africa Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 91. Middle East & Africa Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 92. Middle East & Africa Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 93. Middle East & Africa Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 94. UAE Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 95. UAE Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 96. UAE Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 97. UAE Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 98. Saudi Arabia Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 99. Saudi Arabia Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 100. Saudi Arabia Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 101. Saudi Arabia Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 102. South Africa Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 103. South Africa Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 104. South Africa Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 105. South Africa Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 106. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)
Table 107. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 108. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 109. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 110. Organic Developments in the Pulmonary Arterial Hypertension Market
Table 111. Inorganic Developments in the Pulmonary Arterial Hypertension Market
Table 112. Glossary of Terms
LIST OF FIGURES
Figure 1. Pulmonary Arterial Hypertension Market Segmentation
Figure 2. Pulmonary Arterial Hypertension Market – By Geography
Figure 3. Pulmonary Arterial Hypertension Market Overview
Figure 4. Prostacyclin and Prostacyclin Analogs Segment Held Largest Share by Drugs of Pulmonary Arterial Hypertension Market
Figure 5. Asia Pacific to Show Significant Growth During Forecast Period
Figure 6. Pulmonary Arterial Hypertension Market, by Geography (US$ Million)
Figure 7. Global Pulmonary Arterial Hypertension Market – Leading Country Markets (US$ Million)
Figure 8. Global Pulmonary Arterial Hypertension Market, Industry Landscape
Figure 9. North America: PEST Analysis
Figure 10. Europe: PEST Analysis
Figure 11. Asia Pacific: PEST Analysis
Figure 12. Middle East and Africa: PEST Analysis
Figure 13. South and Central America: PEST Analysis
Figure 14. Experts Opinion
Figure 15. Pulmonary Arterial Hypertension Market Impact Analysis of Drivers and Restraint
Figure 16. Global Pulmonary Arterial Hypertension Market– Revenue Forecast and Analysis – 2020 - 2028
Figure 17. Global Pulmonary Arterial Hypertension Market – By Geography Forecast and Analysis – 2022 - 2028
Figure 18. Market Positioning of Key Players in Pulmonary Arterial Hypertension Market
Figure 19. Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
Figure 20. Endothelin Receptor Antagonists (ERAs): Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Prostacyclin and Prostacyclin Analogs: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. SGC Stimulators: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Pde-5 Dipsticks: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Global Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
Figure 25. Branded: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Generics: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
Figure 28. Oral: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Intravenous/ Subcutaneous: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Inhalational: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
Figure 32. Hospital Pharmacies and Clinics: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Online Pharmacies: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Retail Pharmacies: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. North America: Pulmonary Arterial Hypertension Market, by Key Country – Revenue (2021) (US$ Million)
Figure 36. North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. North America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
Figure 38. US: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. Canada: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. Mexico: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. Europe: Pulmonary Arterial Hypertension Market, by Key Country – Revenue (2021) (US$ Million)
Figure 42. Europe Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 43. Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
Figure 44. Germany: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 45. Germany: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 46. France: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 47. Italy: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 48. Spain: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 49. Rest of Europe: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 50. Asia Pacific: Pulmonary Arterial Hypertension Market, by Key Country – Revenue (2021) (US$ Million)
Figure 51. Asia Pacific Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 52. China: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 53. Japan: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 54. India: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 55. South Korea: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 56. Australia: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 57. Rest of Asia Pacific: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 58. South and Central America: Pulmonary Arterial Hypertension Market, by Key Country – Revenue (2021) (US$ Million)
Figure 59. South and Central America Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Million)
Figure 60. South and Central America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
Figure 61. Brazil: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 62. Argentina: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 63. Rest of South and Central America: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 64. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Key Country – Revenue (2021) (US$ Million)
Figure 65. Middle East & Africa Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (USD Million)
Figure 66. UAE: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 67. Saudi Arabia: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 68. South Africa: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 69. Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)
Figure 70. Impact of COVID-19 Pandemic in North America Country Markets
Figure 71. Impact of COVID-19 Pandemic in European Country Markets
Figure 72. Impact of COVID-19 Pandemic on Asia Pacific Country Markets
Figure 73. Impact of COVID-19 Pandemic in South and Central American Countries
Figure 74. Impact of COVID-19 Pandemic on Middle East and Africa Country Markets
Figure 75. Growth Strategies in the Pulmonary Arterial Hypertension Market (%)
The List of Companies - Butterfly Needles Market
- Johnson & Johnson
- Gilead Sciences Inc
- United Therapeutics Corp
- Bayer AG
- Aerami Therapeutics Holdings Inc
- Novartis AG
- GSK Plc
- Teva Pharmaceutical Industries Ltd
- Lupin Ltd
- Pfizer Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Pulmonary Arterial Hypertension Market
Jan 2023
Infectious Disease Therapeutics Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class (Anti-viral, Anti Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography
Jan 2023
Clinic Casting and Splinting Products Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product [Casting (Casts, Tapes, Cutters, and Casting Accessories) and Splinting (Splints and Splinting Accessories)], Application (Acute Fractures or Sprains, Tendon and Ligament Injuries, and Others), Material (Plaster of Paris, Fiberglass, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2023
Myopia Treatment Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (High Myopia, Degenerative Myopia, Progressive Myopia), Treatment [Low-Dose Atropine Eye Drops, Ortho-K, Contact Lenses, and Refractive Surgery (LASIK, PRK)], Age Group (Adult Myopia and Childhood Myopia), End User (Hospitals and Clinics, Specialty Clinics, and Refractive Surgery Centers), and Geography
Jan 2023
Epilepsy Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Progressive Myoclonic Epilepsy, Reflex Epilepsy, Generalized Epilepsy, and Other), Route of Administration (Oral, Parenteral, and Others), Treatment Type (First-Generation Drugs, Second-Generation Drugs, and Third-Generation Drugs), Age Group (Adults and Children), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography
Jan 2023
Vaccine Adjuvants Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others), Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant), and Geography
Jan 2023
Human Vaccine Adjuvants Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Particulate Adjuvant, Emulsion Adjuvant, Combination Adjuvant, and Others), Application (Influenza, Hepatitis, Human papilloma virus (HPV), and Others), End User (Pharmaceutical and Biotechnology Companies, CMOs and CROs, and Others), and Geography
Jan 2023
Epilepsy Drugs Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment (First-Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-Epileptics), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography
Jan 2023
Specialty Hospitals Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Specialty Type (Pediatric Hospitals, Obstetrics-Gynecology Hospitals, ENT Hospitals, Oncology Hospitals, Rehabilitation Hospitals, Orthopedic Hospitals, Neurology Hospitals, Cardiology Hospitals, IVF Hospitals and Others), Service Type (Outpatient and Inpatient), Hospital Type (Public Hospitals and Private Hospitals), and Geography (North America, Europe, Asia Pacific, and Middle East & Africa)
Get Free Sample For